Influence of apitoxin and melittin from Apis mellifera bee on Staphylococcus aureus strains

Autor(es)

Marques Pereira, Ana Flavia ^[1] ; Albano, Mariana ^[1] ; Bergamo Alves, Fernanda Cristina ^[1] ; Murbach Teles Andrade, Bruna Fernanda ^[1] ; Furlanetto, Alessandra ^[1] ; Mores Rall, Vera Lucia ^[1] ; dos Santos, Lucilene Delazari ^[2] ; Orsi, Ricardo de Oliveira ^[2] ; Fernandes Junior, Ary ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ, Dept Microbiol & Immunol, BR-18618691 Botucatu, SP - Brazil

^[2] Sao Paulo State Univ, CEVAP Ctr Study Venoms & Venomous Anim, BR-18610307 Botucatu, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Microbial Pathogenesis; v. 141, APR 2020.
• Citações Web of Science: 7

Resumo

The antibacterial activities of apitoxin, a venom produced by Apis mellifera bee, and melittin, an antimicrobial peptide from apitoxin, were tested against planktonic and biofilm states of Staphylococcus aureus methicillin-resistant (MRSA), including clinical, and enterotoxin-producing isolates. Also, the synergism of apitoxin and melittin in combination with oxacillin were evaluated as well. The induced morphological changes on S. aureus cells of both products were detected by transmission electronic microscopy (TEM). The minimum inhibitory concentration (MIC) values were 7.2 mu g/mL, and 6.7 mu g/mL, for apitoxin and melittin, respectively. The minimum bactericidal concentration (MBC) values were 28.7 mu g/mL, and 26 mu g/mL for apitoxin and melittin, respectively. The time-kill curve assays of apitoxin or melittin with oxacillin exhibited bactericidal synergism against MRSA isolates. TEM images showed cell distortion, cell disintegration with leakage of cytoplasmic content and loss of cytoplasm content. However, apitoxin and melittin did not interfere with staphylococcal enterotoxin production or release. Thus, apitoxin and melittin are potential agents against MRSA that can serve as possible models for new antibacterial drugs. (AU)

• Processo FAPESP: 15/14278-6 - O impacto de compostos naturais em bactérias de interesse clínico
• Beneficiário: Ary Fernandes Júnior
• Modalidade de apoio: Auxílio à Pesquisa - Regular